Literature DB >> 1101287

Avascular necrosis of bone following renal transplantation.

A M Pierides, W Simpson, D Stainsby, F Alvarez-ude, P R Uldall.   

Abstract

Assessment of 78 successful renal transplants carried out in Newcastle upon Tyne between October 1967 and March 1973, revealed avascular necrosis of bone (A.N.) in 11 patients (14 percent). Pain and restriction of movement were the cardinal symptoms, while the onset was from five to 35 months after transplantation. In some patients one joint only was affected but in seven patients (64 per cent) A.N. developed in other joints too in an additive and progressive fashion. A time lag was usually noted between the onset of symptoms and radiological proof. These 11 patients with A.N. were compared with two control groups of unaffected renal transplant patients. Taking into account the patients' body weight, the cumulative dose of prednisone received by affected patients during the first three post-transplant months was found to be significantly higher than that for both control groups (P less than 0.05). Patients with A.N. were found to have had an unusually high incidence of early post-transplant surgical complications and the length of their initial stay in hospital was significantly prolonged (P less than 0.02) when compared to both control groups. It is possible that excessive corticosteroid therapy is more deleterious in transplant patients weakened by peri-renal haematomas, urinary extravasations and stormy prolonged post-operative periods. Having emphasized the detrimental effects of excessive anti-rejection corticosteroid therapy it must be mentioned that occasionally patients develop avascular necrosis even after low doses of steroid therapy, while others, receiving high doses of steroid therapy and undergoing a stormy post-operative course, do not develop this complaint. It is suggested that although excessive steroid therapy is positively harmful, avascular necrosis is not an invariable complication and that ofther factors including possibly a genetic predisposition operate to produce avascular necrosis of bone in renal transplant patients.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1101287

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  7 in total

Review 1.  Steroid induced osteonecrosis: An analysis of steroid dosing risk.

Authors:  Christian Powell; Christopher Chang; Stanley M Naguwa; Gurtej Cheema; M Eric Gershwin
Journal:  Autoimmun Rev       Date:  2010-07-09       Impact factor: 9.754

2.  Ischaemia of bone.

Authors:  M Catto
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1977

3.  Avascular necrosis of bone complicating corticosteroid replacement therapy.

Authors:  P L Williams; M Corbett
Journal:  Ann Rheum Dis       Date:  1983-06       Impact factor: 19.103

4.  Corticosteroid administration within 2 weeks after renal transplantation affects the incidence of femoral head osteonecrosis.

Authors:  Masazumi Saito; Keiichiro Ueshima; Mikihiro Fujioka; Masashi Ishida; Tsuyoshi Goto; Yuji Arai; Kazuya Ikoma; Hiroyoshi Fujiwara; Wakaba Fukushima; Toshikazu Kubo
Journal:  Acta Orthop       Date:  2014-04-30       Impact factor: 3.717

5.  Chronic pain 1-5 years after heart transplantation-A nationwide cross-sectional cohort study.

Authors:  Marita Dalvindt; Annika Kisch; Shahab Nozohoor; Annette Lennerling; Anna Forsberg
Journal:  Nurs Open       Date:  2020-04-27

6.  Avascular osteonecrosis in kidney transplant recipients: Risk factors in a recent cohort study and evaluation of the role of secondary hyperparathyroidism.

Authors:  Renaud Felten; Peggy Perrin; Sophie Caillard; Bruno Moulin; Rose-Marie Javier
Journal:  PLoS One       Date:  2019-02-22       Impact factor: 3.240

Review 7.  High-Dose Corticosteroid Use and Risk of Hip Osteonecrosis: Meta-Analysis and Systematic Literature Review.

Authors:  Michael A Mont; Robert Pivec; Samik Banerjee; Kimona Issa; Randa K Elmallah; Lynne C Jones
Journal:  J Arthroplasty       Date:  2015-04-08       Impact factor: 4.757

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.